Bausch + Lomb Corporation reported a revenue increase of 9% for the first quarter of 2026, reaching $1.244 billion compared to $1.137 billion in the same period last year. This growth was driven by a combination of factors, including a favorable foreign currency impact of $42 million, increased net pricing of $38 million, and higher volumes contributing an additional $29 million. The company's Vision Care segment led the revenue growth with an 8% increase, while the Pharmaceuticals segment saw a 14% rise, and the Surgical segment grew by 7%. Despite the revenue growth, Bausch + Lomb recorded a net loss of $71 million, an improvement from a loss of $212 million in the prior year.
In terms of operational performance, Bausch + Lomb's gross profit margin improved, with cost of goods sold remaining relatively stable at $482 million, compared to $481 million in the previous year. The company reported an operating income of $33 million, a significant turnaround from an operating loss of $83 million in Q1 2025. This improvement was attributed to increased revenues and a reduction in selling, general, and administrative expenses, which decreased by 3% to $544 million.
Strategically, Bausch + Lomb has been active in expanding its product offerings and capabilities. The company completed the acquisition of a manufacturing facility in Mexico in December 2025, which is expected to enhance its manufacturing capacity and margins. Additionally, the acquisition of Whitecap Biosciences in January 2025 is anticipated to bolster its clinical-stage pipeline with innovative therapies for glaucoma and geographic atrophy. The company continues to explore further strategic acquisitions and licensing agreements to enhance its product portfolio.
Bausch + Lomb's workforce has also seen changes, with a focus on optimizing operations and reducing costs. The company reported a headcount that reflects ongoing restructuring efforts aimed at improving operational efficiency. As of March 31, 2026, the company had approximately 900 employees dedicated to research and development, focusing on advancing its product pipeline, which includes new contact lenses and treatments for various eye conditions.
Looking ahead, Bausch + Lomb remains cautious about macroeconomic conditions, including inflation and geopolitical tensions, which could impact its operations. The company is also monitoring the potential effects of tariffs and trade restrictions on its business. Despite these challenges, Bausch + Lomb is optimistic about its growth prospects, driven by its robust product pipeline and strategic initiatives aimed at enhancing its market position in the eye health sector.
About Bausch & Lomb Corp
Bausch + Lomb Corporation is a global eye health company offering a comprehensive portfolio of approximately 400 products across Vision Care, Pharmaceuticals, and Surgical segments. Its products include contact lenses, lens care solutions, ophthalmic pharmaceuticals, intraocular lenses, and surgical devices. Serving patients, consumers, and eye care professionals worldwide, Bausch + Lomb leverages innovation, strong brand equity, and integrated R&D to address diverse eye health needs through a fully integrated business model.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.